Shares of Catasys, Inc. (NASDAQ:CATS) have received a consensus broker rating score of 2.00 (Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a buy rating. Catasys’ rating score has declined by 33.3% from 90 days ago as a result of various analysts’ upgrades and downgrades.

Analysts have set a one year consensus price target of $5.30 for the company and are forecasting that the company will post ($0.09) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Catasys an industry rank of 168 out of 265 based on the ratings given to related companies.

Separately, Zacks Investment Research lowered Catasys from a “hold” rating to a “sell” rating in a report on Tuesday, December 19th.

A hedge fund recently bought a new stake in Catasys stock. Weber Alan W purchased a new stake in shares of Catasys, Inc. (NASDAQ:CATS) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 108,165 shares of the company’s stock, valued at approximately $406,000. Weber Alan W owned 0.68% of Catasys as of its most recent filing with the SEC. 5.98% of the stock is owned by hedge funds and other institutional investors.

Catasys (CATS) traded up $0.06 during trading hours on Thursday, reaching $4.38. The company had a trading volume of 9,999 shares, compared to its average volume of 69,574. Catasys has a one year low of $3.30 and a one year high of $14.00. The stock has a market cap of $68.64, a price-to-earnings ratio of -4.25 and a beta of 0.10.

ILLEGAL ACTIVITY WARNING: This piece was reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at

Catasys Company Profile

Catasys, Inc provides data analytics based specialized behavioral health management and integrated treatment services to health plans and other third party payors. It offers OnTrak solution to improve treatment outcomes and lower the utilization of medical and behavioral health plan services. The company’s OnTrak solution includes medical and psychosocial interventions; and a proprietary Web based clinical information platform and database, psychosocial programs, and integrated care coaching services.

Get a free copy of the Zacks research report on Catasys (CATS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Catasys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catasys and related companies with's FREE daily email newsletter.